Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email email@example.com.
Check back regularly for news, coverage, and announcements about MAVA.
New Enterprise Associates (NEA), one of the largest venture capital firms around, is raising its 15th fund.
Cortendo AB has agreed to receive up to $27.5 million in a private placement.
Sensory NeuroStimulation, Inc., makers of the Relaxis™ device for treating Restless Legs Syndrome (RLS), has entered into a new credit agreement with Silicon Valley Bank, the company announced today.
Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting, has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. for a term loan of up to $26.0 million and completed a private placement for $1.0 million of Cerulean common stock with Hercules.
Trevi Therapeutics, Inc., a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender.
Welltok, developer of the CafeWell Health Optimization Platform, officially closed its most recent funding round of $37 million.
Trevi Therapeutics has secured a $15 million senior loan from Solar Capital and Square 1 Bank.
Surface Oncology has secured $35 million in Series A funding.
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding.
Biotech accelerator Cydan Development Inc. announced Wednesday $25 million in Series A funding to launch Vtesse Inc., which will focus on developing treatments for lysosomal storage diseases, a collection of rare, typically fatal disorders usually affecting children.